Crinetics Presents Clinical and Research Results at ENDO 2022
June 08, 2022 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, June 08, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced that results from the company’s Phase 1 study of CRN04894, the company’s investigational...
Crinetics Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference
June 07, 2022 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel...
Crinetics Pharmaceuticals Reports Positive Top-line Results Including Strong Adrenal Suppression from CRN04894 Phase 1 Study Multiple-Ascending Dose Cohorts
May 25, 2022 07:00 ET
|
Crinetics Pharmaceuticals, Inc.
Patient Studies in Cushing’s Disease and Congenital Adrenal Hyperplasia to Initiate Later this Year Management Hosting Webcast and Conference Call Today to Discuss Findings at 8:00 a.m. Eastern Time ...
Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 12, 2022 16:42 ET
|
Crinetics Pharmaceuticals, Inc.
Phase 1 Multiple-Ascending Dose Data for CRN04894 Expected in 2Q22 Paltusotine’s Phase 3 PATHFNDR Trials in Acromegaly Advancing Towards Anticipated Top-Line Data Readouts in 2023Clinical Trial of...
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 10, 2022 16:18 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Announces Closing of Underwritten Common Stock Offering
April 18, 2022 16:01 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering
April 12, 2022 23:50 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, April 12, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 11, 2022 17:15 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, April 11, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
March 30, 2022 16:02 ET
|
Crinetics Pharmaceuticals, Inc.
– Pipeline Includes Three New Chemical Entities with Clinical Proof-Of-Concept (POC) Following CRN04894 and CRN04777 Phase 1 Readouts in 2021 – – Advancing Phase 3 PATHFNDR Program Evaluating...
Crinetics Pharmaceuticals Reports Positive Top-Line Results from CRN04777 Phase 1 Study Multiple-Ascending Dose Cohorts
March 30, 2022 16:01 ET
|
Crinetics Pharmaceuticals, Inc.
Results Further Support Clinical Proof-of-Concept for CRN04777 by Showing Dose-Dependent Decreases in Fasting and Sulfonylurea-Induced Insulin Secretion Management Hosting Webcast and Conference Call...